Columbia’s Progesterone Faces FDA Skepticism Over Foreign Data At Advisory Committee

The agency rejects the sponsor’s statistical analysis and says there is no statistically significant evidence of efficacy in the U.S. population, and the product seems likely to face a request for another trial from the advisory panel.

More from United States

More from North America